Developer docs
API playgroundTry for free, no card

Search company profiles

Poolbeg Pharma

Full company profile

uuid0000n1a

Namestring
Poolbeg Pharma
Legal namestring
Poolbeg Pharma Plc
Company typeenum
Public
Founded yearint
2021
Descriptiontext

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company listed on the London Stock Exchange's AIM market (ticker: POLB) and dual-headquartered in London and Dublin. Founded in July 2021 as a spin-out from hVIVO plc (formerly Open Orphan plc), the company develops small-molecule and oral biologics targeting infectious disease, cancer immunotherapy side effects, and metabolic disease. Its lead asset, POLB 001, is an oral p38 MAP kinase inhibitor being developed in two indications: prevention of cytokine release syndrome (CRS) in cancer immunotherapy patients and treatment of severe influenza. POLB 001 received FDA Orphan Drug Designation in May 2025 and is currently in a Phase IIa TOPICAL trial (activated June 2026, interim data expected summer 2026) across six NHS sites, with Johnson & Johnson providing its bispecific antibody teclistamab as part of the RISE research programme. A second programme applies AnaBio Technologies' pH-sensitive microencapsulation platform to develop an oral GLP-1 receptor agonist for obesity, currently in preclinical proof-of-concept at the University of Ulster.

The company's business model is asset-light and licensing-oriented. As a clinical-stage developer with no commercial products, Poolbeg intends to monetize its pipeline through licensing or partnership deals with large pharmaceutical companies following proof-of-concept clinical data, rather than building its own commercialization infrastructure. It pursues cost-efficient clinical trials designed to produce high-quality human data that accelerate partnering discussions. The company supplements its internal pipeline with AI-led drug discovery programmes for influenza (with CytoReason) and RSV (with OneThree Biotech), leveraging its inherited repository of 20+ years of human challenge trial data as a competitive differentiator. Poolbeg holds a global patent estate covering POLB 001 across the US, Europe, Japan, Australia, and Canada, with potential protection extending to 2044 in oncology indications.

The company serves three primary constituencies: (1) large pharmaceutical companies developing cancer immunotherapies and metabolic disease therapeutics, who are the intended licensing counterparties; (2) cancer treatment centers and hospitals that would administer POLB 001 alongside bispecific antibodies and CAR T-cell therapies to enable safer, outpatient administration; and (3) patients with multiple myeloma, DLBCL, severe influenza, or obesity who stand to benefit from the company's pipeline candidates. Poolbeg is debt-free with a £10m cash balance and runway into 2027, supported by an oversubscribed £4.1m equity raise completed in June 2025.

Short descriptiontext

Poolbeg Pharma is a clinical-stage biopharmaceutical company developing POLB 001, an oral p38 MAPK inhibitor for cancer immunotherapy-induced cytokine release syndrome and severe influenza, alongside an oral GLP-1 obesity therapy, with a licensing-oriented business model targeting large pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
infectious disease therapeutics, cancer immunotherapy CRS prevention, oral GLP-1 obesity therapy, AI drug discovery, p38 MAPK inhibitor
Industry2 codes
PRIMARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-stage biopharmaceutical drug development
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Partnership Deals
TypeLicensing Royalties
Description

Poolbeg Pharma's primary revenue strategy is to partner with large pharmaceutical companies for licensing deals after generating proof-of-concept clinical data. The company aims to maximize value through significant transactions with pharma partners.

poolbegpharma.com
2Future Product Sales
TypeHardware Sales
Description

Pre-revenue clinical stage company. Potential future revenue from product sales if any drug candidates receive regulatory approval and are commercialized.

poolbegpharma.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Poolbeg Pharma is a clinical-stage biopharmaceutical company developing drug candidates for infectious diseases, cancer immunotherapy complications, and metabolic disease. Its lead asset, POLB 001, is an oral p38 MAP kinase inhibitor being developed to prevent cytokine release syndrome (CRS) in cancer immunotherapy patients and for severe influenza. The company is also advancing an oral encapsulated GLP-1 therapy for obesity and operating AI-led drug discovery programmes for influenza and RSV leveraging proprietary human challenge trial data.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • TNF-α reduction of 73.5% and 56.2% for 70mg and 150mg doses respectively in LPS challenge trial
+5 more records
Product overview1 text field

Poolbeg Pharma is a clinical-stage biopharmaceutical company with a portfolio of drug development programmes. The core products include POLB 001 (an oral p38 MAPK inhibitor) being developed for two indications: cancer immunotherapy-induced CRS (cytokine release syndrome prevention) and severe influenza treatment. The company is also developing an Oral Encapsulated GLP-1 therapy for obesity using proprietary microencapsulation technology. Additionally, Poolbeg operates AI-led drug discovery programmes for influenza and RSV, leveraging unique human challenge trial data combined with AI合作伙伴 (CytoReason and OneThree Biotech) to identify novel drug targets and candidates.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-09
Description

J&J providing its bispecific antibody for use in Poolbeg's TOPICAL trial within the RISE research programme. The RISE programme focuses on understanding and managing CRS related to cancer immunotherapies. Collaboration aims to facilitate safer administration of immunotherapies by researching CRS prevention methods.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-11-15
Description

Collaboration with AnaBio Technologies for oral vaccine programme using proprietary encapsulation technology. Irish Government's Disruptive Technologies Innovation Fund awarded €2.3m non-dilutive grant to the consortium. Validating encapsulation process to develop Phase I clinical trial-ready oral vaccine candidate. Technology also being applied to oral GLP-1 programme.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-03-24
Description

Partnership with leading AI company CytoReason to analyze Poolbeg's unique influenza disease progression data. Harnesses insights from Poolbeg's repository of influenza human challenge trial data together with CytoReason's curated disease data and validated AI technology. Successfully identified multiple novel drug targets for influenza.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-02-24
Description

Partnership with biology-driven AI company OneThree Biotech to identify new treatments for RSV. Poolbeg's scientific team worked closely with OneThree to build tailored AI approach leveraging unique RSV human challenge trial data. Successfully identified disease-relevant pathways and drug candidates, with positive outputs from lab-based analysis.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-17
Description

Licensed RNA-based immunotherapy for respiratory viruses from University of Warwick. Acquired immunotherapy candidate for further development.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

ACT appointed to conduct Phase IIa TOPICAL trial of POLB 001. Specialist blood cancer trials organization running the trial across multiple NHS sites.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

One of six NHS hospital sites conducting the TOPICAL trial. The Christie is a specialist cancer center and Chief Investigator site.

8The Royal Marsden
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

NHS hospital site participating in TOPICAL trial for POLB 001.

poolbegpharma.com
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

NHS hospital site participating in TOPICAL trial for POLB 001.

10University Hospitals Birmingham
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

NHS hospital site participating in TOPICAL trial for POLB 001.

poolbegpharma.com
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

NHS hospital site in Scotland participating in TOPICAL trial for POLB 001.

12Royal Stoke University Hospital
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

NHS hospital site participating in TOPICAL trial for POLB 001.

poolbegpharma.com
13University of Ulster
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

University of Ulster conducting proof of concept trial for oral encapsulated GLP-1 programme. Prof Carel le Roux serves as trial investigator.

poolbegpharma.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage inflammation/immunology biotech working on immune-mediated diseases, including oncology supportive care adjacencies. Comparable small-cap clinical-stage profile.

TypeDirect peer
Description

Clinical-stage immunology company developing antibodies for inflammatory and immunologically-mediated diseases, including cytokine release considerations. Comparable clinical-stage development model and inflammation focus.

3Inflazome Ltd
TypeDirect peer
Description

Direct historical peer in p38 MAPK/NLRP3 inhibitor development, acquired by Roche for $450M+ in 2020. CEO Jeremy Skillington was previously VP BD at Inflazome, making this the most comparable corporate trajectory for Poolbeg.

TypeDirect peer
Description

Poolbeg's former parent (spun out in 2021). Operates human challenge trial services for respiratory viruses including influenza and RSV — directly linked to Poolbeg's data assets and the source of its human challenge trial data moat.

5Valneva SE
TypeDirect peer
Description

European clinical-stage biopharma developing vaccines and therapeutics for infectious diseases. Comparable size, AIM/Euronext listing, and similar infectious disease focus including influenza programmes.

TypeDirect peer
Description

UK AIM-listed clinical-stage immunology biotech developing cancer immunotherapies and infectious disease vaccines. Similar size, listing venue, and pipeline mix of immunology and infectious disease programmes.

TypeEmerging player
Description

AI-driven drug discovery company. Poolbeg's AI programmes with CytoReason and OneThree Biotech follow a similar computational biology/drug discovery paradigm, although at earlier stage and narrower scope.

TypeRegional player
Description

UK/EU-based AI drug discovery company applying machine learning to identify novel therapeutic targets. Comparable in applying AI to pharmaceutical R&D, though focused on different disease areas.

TypeRegional player
Description

UK AIM-listed clinical-stage company with a similar small-cap profile. Adjacent in oncology/immunology focus, useful as a regional market comparable for AIM-listed clinical-stage UK biotechs.

TypeOthers
Description

AI partner of Poolbeg for the influenza programme. Adjacent technology provider whose disease-models platform is integrated into Poolbeg's AI drug discovery workflow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Poolbeg Pharma

Clinical-stage biopharmaceutical drug developmentpoolbegpharma.com

Poolbeg Pharma is a clinical-stage biopharmaceutical company developing POLB 001, an oral p38 MAPK inhibitor for cancer immunotherapy-induced cytokine release syndrome and severe influenza, alongside an oral GLP-1 obesity therapy, with a licensing-oriented business model targeting large pharmaceutical partners.

What Poolbeg Pharma does

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company listed on the London Stock Exchange's AIM market (ticker: POLB) and dual-headquartered in London and Dublin. Founded in July 2021 as a spin-out from hVIVO plc (formerly Open Orphan plc), the company develops small-molecule and oral biologics targeting infectious disease, cancer immunotherapy side effects, and metabolic disease. Its lead asset, POLB 001, is an oral p38 MAP kinase inhibitor being developed in two indications: prevention of cytokine release syndrome (CRS) in cancer immunotherapy patients and treatment of severe influenza. POLB 001 received FDA Orphan Drug Designation in May 2025 and is currently in a Phase IIa TOPICAL trial (activated June 2026, interim data expected summer 2026) across six NHS sites, with Johnson & Johnson providing its bispecific antibody teclistamab as part of the RISE research programme. A second programme applies AnaBio Technologies' pH-sensitive microencapsulation platform to develop an oral GLP-1 receptor agonist for obesity, currently in preclinical proof-of-concept at the University of Ulster.

The company's business model is asset-light and licensing-oriented. As a clinical-stage developer with no commercial products, Poolbeg intends to monetize its pipeline through licensing or partnership deals with large pharmaceutical companies following proof-of-concept clinical data, rather than building its own commercialization infrastructure. It pursues cost-efficient clinical trials designed to produce high-quality human data that accelerate partnering discussions. The company supplements its internal pipeline with AI-led drug discovery programmes for influenza (with CytoReason) and RSV (with OneThree Biotech), leveraging its inherited repository of 20+ years of human challenge trial data as a competitive differentiator. Poolbeg holds a global patent estate covering POLB 001 across the US, Europe, Japan, Australia, and Canada, with potential protection extending to 2044 in oncology indications.

The company serves three primary constituencies: (1) large pharmaceutical companies developing cancer immunotherapies and metabolic disease therapeutics, who are the intended licensing counterparties; (2) cancer treatment centers and hospitals that would administer POLB 001 alongside bispecific antibodies and CAR T-cell therapies to enable safer, outpatient administration; and (3) patients with multiple myeloma, DLBCL, severe influenza, or obesity who stand to benefit from the company's pipeline candidates. Poolbeg is debt-free with a £10m cash balance and runway into 2027, supported by an oversubscribed £4.1m equity raise completed in June 2025.

Poolbeg Pharma firmographics

Firmographics
Name
Poolbeg Pharma
Legal name
Poolbeg Pharma Plc
Website
https://poolbegpharma.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Poolbeg Pharma is a clinical-stage biopharmaceutical company developing POLB 001, an oral p38 MAPK inhibitor for cancer immunotherapy-induced cytokine release syndrome and severe influenza, alongside an oral GLP-1 obesity therapy, with a licensing-oriented business model targeting large pharmaceutical partners.
Ownership category
akta.pro rank

Poolbeg Pharma industry classification

Industry
Product category
Clinical-stage biopharmaceutical drug development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Infectious disease therapeutics
  • Cancer immunotherapy CRS prevention
  • Oral GLP-1 obesity therapy
  • AI drug discovery
  • P38 MAPK inhibitor

Where Poolbeg Pharma is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Poolbeg Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing and Partnership Deals: Poolbeg Pharma's primary revenue strategy is to partner with large pharmaceutical companies for licensing deals after generating proof-of-concept clinical data. The company aims to maximize value through significant transactions with pharma partners.
  2. Future Product Sales: Pre-revenue clinical stage company. Potential future revenue from product sales if any drug candidates receive regulatory approval and are commercialized.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels9 records

Poolbeg Pharma product offering

Product offering

Core offering

Poolbeg Pharma is a clinical-stage biopharmaceutical company developing drug candidates for infectious diseases, cancer immunotherapy complications, and metabolic disease. Its lead asset, POLB 001, is an oral p38 MAP kinase inhibitor being developed to prevent cytokine release syndrome (CRS) in cancer immunotherapy patients and for severe influenza. The company is also advancing an oral encapsulated GLP-1 therapy for obesity and operating AI-led drug discovery programmes for influenza and RSV leveraging proprietary human challenge trial data.

Product overview

Poolbeg Pharma is a clinical-stage biopharmaceutical company with a portfolio of drug development programmes. The core products include POLB 001 (an oral p38 MAPK inhibitor) being developed for two indications: cancer immunotherapy-induced CRS (cytokine release syndrome prevention) and severe influenza treatment. The company is also developing an Oral Encapsulated GLP-1 therapy for obesity using proprietary microencapsulation technology. Additionally, Poolbeg operates AI-led drug discovery programmes for influenza and RSV, leveraging unique human challenge trial data combined with AI合作伙伴 (CytoReason and OneThree Biotech) to identify novel drug targets and candidates.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • TNF-α reduction of 73.5% and 56.2% for 70mg and 150mg doses respectively in LPS challenge trial
  • +5 more outcomes

Companies that use Poolbeg Pharma

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Poolbeg Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Poolbeg Pharma partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • Johnson & JohnsoncoreStrategic or Co-development Partner · 9 December 2025J&J providing its bispecific antibody for use in Poolbeg's TOPICAL trial within the RISE research programme. The RISE programme focuses on understanding and managing CRS related to cancer immunotherapies. Collaboration aims to facilitate safer administration of immunotherapies by researching CRS prevention methods.
  • AnaBio TechnologiescoreTechnology or Integration · 15 November 2022Collaboration with AnaBio Technologies for oral vaccine programme using proprietary encapsulation technology. Irish Government's Disruptive Technologies Innovation Fund awarded €2.3m non-dilutive grant to the consortium. Validating encapsulation process to develop Phase I clinical trial-ready oral vaccine candidate. Technology also being applied to oral GLP-1 programme.
  • CytoReasoncoreTechnology or Integration · 24 March 2022Partnership with leading AI company CytoReason to analyze Poolbeg's unique influenza disease progression data. Harnesses insights from Poolbeg's repository of influenza human challenge trial data together with CytoReason's curated disease data and validated AI technology. Successfully identified multiple novel drug targets for influenza.
  • OneThree BiotechcoreTechnology or Integration · 24 February 2022Partnership with biology-driven AI company OneThree Biotech to identify new treatments for RSV. Poolbeg's scientific team worked closely with OneThree to build tailored AI approach leveraging unique RSV human challenge trial data. Successfully identified disease-relevant pathways and drug candidates, with positive outputs from lab-based analysis.
  • University of WarwickminorStrategic or Co-development Partner · 17 January 2022Licensed RNA-based immunotherapy for respiratory viruses from University of Warwick. Acquired immunotherapy candidate for further development.
  • Accelerating Clinical Trials (ACT)coreImplementation/ SI/ Consulting PartnerACT appointed to conduct Phase IIa TOPICAL trial of POLB 001. Specialist blood cancer trials organization running the trial across multiple NHS sites.
  • The Christie NHS Foundation TrustcoreImplementation/ SI/ Consulting PartnerOne of six NHS hospital sites conducting the TOPICAL trial. The Christie is a specialist cancer center and Chief Investigator site.
  • The Royal MarsdencoreImplementation/ SI/ Consulting PartnerNHS hospital site participating in TOPICAL trial for POLB 001.
  • University College London HospitalscoreImplementation/ SI/ Consulting PartnerNHS hospital site participating in TOPICAL trial for POLB 001.
  • University Hospitals BirminghamcoreImplementation/ SI/ Consulting PartnerNHS hospital site participating in TOPICAL trial for POLB 001.
  • NHS Lothian (Edinburgh)coreImplementation/ SI/ Consulting PartnerNHS hospital site in Scotland participating in TOPICAL trial for POLB 001.
  • Royal Stoke University HospitalcoreImplementation/ SI/ Consulting PartnerNHS hospital site participating in TOPICAL trial for POLB 001.
  • University of UlstercoreImplementation/ SI/ Consulting PartnerUniversity of Ulster conducting proof of concept trial for oral encapsulated GLP-1 programme. Prof Carel le Roux serves as trial investigator.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Poolbeg Pharma competitors and assessment

Company assessment

Emerging players

  • Evelo Biosciences: Clinical-stage inflammation/immunology biotech working on immune-mediated diseases, including oncology supportive care adjacencies. Comparable small-cap clinical-stage profile.
  • Recursion Pharmaceuticals: AI-driven drug discovery company. Poolbeg's AI programmes with CytoReason and OneThree Biotech follow a similar computational biology/drug discovery paradigm, although at earlier stage and narrower scope.

Direct peers

  • AnaptysBio Inc: Clinical-stage immunology company developing antibodies for inflammatory and immunologically-mediated diseases, including cytokine release considerations. Comparable clinical-stage development model and inflammation focus.
  • Inflazome Ltd: Direct historical peer in p38 MAPK/NLRP3 inhibitor development, acquired by Roche for $450M+ in 2020. CEO Jeremy Skillington was previously VP BD at Inflazome, making this the most comparable corporate trajectory for Poolbeg.
  • hVIVO plc: Poolbeg's former parent (spun out in 2021). Operates human challenge trial services for respiratory viruses including influenza and RSV — directly linked to Poolbeg's data assets and the source of its human challenge trial data moat.
  • Valneva SE: European clinical-stage biopharma developing vaccines and therapeutics for infectious diseases. Comparable size, AIM/Euronext listing, and similar infectious disease focus including influenza programmes.
  • Scancell Holdings plc: UK AIM-listed clinical-stage immunology biotech developing cancer immunotherapies and infectious disease vaccines. Similar size, listing venue, and pipeline mix of immunology and infectious disease programmes.

Regional players

  • Benevolent AI: UK/EU-based AI drug discovery company applying machine learning to identify novel therapeutic targets. Comparable in applying AI to pharmaceutical R&D, though focused on different disease areas.
  • Oncimmune Holdings plc: UK AIM-listed clinical-stage company with a similar small-cap profile. Adjacent in oncology/immunology focus, useful as a regional market comparable for AIM-listed clinical-stage UK biotechs.

Others

  • CytoReason: AI partner of Poolbeg for the influenza programme. Adjacent technology provider whose disease-models platform is integrated into Poolbeg's AI drug discovery workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Poolbeg Pharma social profiles

Digital presence

Poolbeg Pharma compliance and trust

Trust signal

Compliance1 record

Poolbeg Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Poolbeg Pharma leadership team

Management profile

Number of profiles

Profiles6 records

Poolbeg Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Poolbeg Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Poolbeg Pharma

What does Poolbeg Pharma do?

Poolbeg Pharma is a clinical-stage biopharmaceutical company developing drug candidates for infectious diseases, cancer immunotherapy complications, and metabolic disease. Its lead asset, POLB 001, is an oral p38 MAP kinase inhibitor being developed to prevent cytokine release syndrome (CRS) in cancer immunotherapy patients and for severe influenza. The company is also advancing an oral encapsulated GLP-1 therapy for obesity and operating AI-led drug discovery programmes for influenza and RSV leveraging proprietary human challenge trial data.

Is Poolbeg Pharma a public or private company?

Poolbeg Pharma is a public company. It is classified as public and is currently operating.

When was Poolbeg Pharma founded?

Poolbeg Pharma was founded in 2021. It employs 11 to 50 people.

Where is Poolbeg Pharma based?

Poolbeg Pharma is headquartered in London, United Kingdom, in the Europe region.

How does Poolbeg Pharma make money?

Two revenue lines are on record. Licensing and Partnership Deals are the primary driver. The others are future Product Sales.

Who are Poolbeg Pharma's main competitors?

Emerging players on record are Evelo Biosciences and Recursion Pharmaceuticals. Direct peers are AnaptysBio Inc, Inflazome Ltd, hVIVO plc, Valneva SE and Scancell Holdings plc. Regional players are Benevolent AI and Oncimmune Holdings plc. CytoReason is listed as an others.

Does Poolbeg Pharma have an API?

No public API is recorded for Poolbeg Pharma.

What industry is Poolbeg Pharma in?

Poolbeg Pharma's product category is Clinical-stage biopharmaceutical drug development. Its primary akta.pro industry code is HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine), with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comPoolbeg Pharma receives South Korea patent for POLB 001Poolbeg Pharma announced South Korea granted a patent for POLB 001, a p38 MAP kinase inhibitor for cancer immunotherapy-associated cytokine release syndrome. The patent expires in 2044 and adds to the company's international patent estate. The CEO said it enhances the drug's attractiveness to prospective partners.InvestegatePOLB 001 TOPICAL trial recruitment updatePoolbeg Pharma announced that recruitment for its POLB 001 TOPICAL trial is progressing well, with eight participants dosed out of approximately 30 since the first patient was dosed in July 2026. The trial evaluates POLB 001 as a preventative therapy for Cytokine Release Syndrome in multiple myeloma patients receiving teclistamab, and further clinical sites have expressed interest in joining.Markets DailyPoolbeg Pharma (LON:POLB) Earns “House Stock” Rating from Shore Capital GroupShore Capital Group reaffirmed its 'house stock' rating on Poolbeg Pharma, citing a positive interim review of the POLB 001 TOPICAL trial. The review found no safety-related reason to pause, modify, or terminate the trial, which targets cytokine release syndrome prevention. Investors may await further efficacy data before assigning greater value.Irish ExaminerIrish biotech's cancer drug trial cleared to continuePoolbeg Pharma's interim safety review cleared its TOPICAL trial to continue unchanged, recruiting at UK sites. The trial tests POLB 001, an oral drug to prevent cytokine release syndrome, which affects 60-80% of patients on bispecific antibodies and CAR-T therapies. The company plans to license the drug to a larger drugmaker once it reaches a clinical inflection point.InvestegateInterim data from POLB 001 TOPICAL clinical trialPoolbeg Pharma announced a positive interim review of its TOPICAL clinical trial, recommending the study continue as planned. Recruitment is ongoing at UK sites, with further patients expected. The trial evaluates POLB 001 as a CRS preventative for multiple myeloma patients receiving teclistamab.InvestegateNotification of Major HoldingsMichael Kelly notified Poolbeg Pharma PLC of a change in his major shareholding, crossing a threshold on August 29, 2026. He now holds 6.27% of voting rights, equivalent to 47,894,457 shares, up from 5.67% previously. The notification was made to the issuer on September 12, 2026.Investing.comMichael Kelly reduces stake in Poolbeg Pharma to 5.67% By Investing.comMichael Kelly's shareholding in Poolbeg Pharma PLC fell below the 6% threshold to 5.67% on July 21, 2026, according to a regulatory filing with the London Stock Exchange's Regulatory News Service. The stake reduction represents 43,314,547 voting rights attached to shares, down from the previous holding of 6.14%. Kelly holds the voting rights directly with no financial instruments involved in the position.ProactiveinvestorsTesla to roll out AI-powered Grok voice assistant, self-driving stat sharingPoolbeg Pharma PLC has secured a Notice of Allowance from the Israeli Patent Office for its POLB 001 cancer immunotherapy-induced cytokine release syndrome patent application, following grants already received in Europe, Australia, and Canada. The clinical-stage biopharmaceutical company is developing POLB 001 as a potentially preventative oral therapy for cytokine release syndrome, a serious and sometimes life-threatening immune reaction triggered by certain cancer treatments. The board stated that the growing patent estate strengthens the strategic and commercial appeal of POLB 001 to potential partners as it advances through clinical development.ProactiveinvestorsPoolbeg wins Israeli patent nod for lead cancer immunotherapy drugPoolbeg Pharma PLC has secured a Notice of Allowance from the Israeli Patent Office for its POLB 001 cancer immunotherapy-induced cytokine release syndrome patent application. The clinical-stage biopharmaceutical company is developing POLB 001 as a potentially preventative oral therapy for cytokine release syndrome, a serious immune reaction triggered by certain cancer treatments, with the Israeli decision following prior grants in Europe, Australia, and Canada. The board stated that the growing patent estate strengthens the strategic and commercial appeal of POLB 001 to potential partners as it advances through clinical development.YahooACG Metals, Rockfire Resources, Sunda Energy, CelLBxHealth, Poolbeg PharmaceuticalACG Metals exceeded its full-year oxide production target within six months, driven by a 64% increase in realized gold prices to $4,838 per ounce. Rockfire Resources reported high zinc grades at its Greek project and is fast-tracking feasibility studies, while Sunda Energy applied for exploration permits in New Zealand's Taranaki Basin.